Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access

Executive Summary

Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies

You may also be interested in...



Ipsen, Invida Group Sign Agreement To Commercialize Drugs In South-East Asia

SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region

Ipsen's First Focus Is Endocrinology As Firm Moves Toward Specialty Care

As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.

UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets

For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel